Enfortumab Vedotin (NCT07475806)

Name: Enfortumab Vedotin trial for Muscle-invasive Bladder Cancer (NCT07475806)
Uploaded: 2026-10-31T06:27:57.618Z
Duration: 1 min 23 s
Description: Enfortumab Vedotin trial for Muscle-invasive Bladder Cancer (NCT07475806). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07475806.

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder: a one-minute explainerNCT074758061 min

Enfortumab Vedotin trial for Muscle-invasive Bladder Cancer (NCT07475806). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with qualifying nonmetastatic, muscle-invasive bladder cancer who are eligible for bladder-removal surgery. Prior systemic bladder-cancer treatment or checkpoint immunotherapy is excluded.

The idea: enfortumab vedotin delivers a cell-division blocker to nectin-4-bearing cells; pembrolizumab releases immune brakes. Both are intravenous. Researchers test whether treatment can preserve the bladder. Patients without complete response after nine cycles, or with progression, may need other treatment, including surgery.

This phase 2 study plans 240 patients. Astellas sponsors it, with 19 recruiting US sites. Bladder preservation is an outcome being tested.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.